Pharma Pulse 4/22/25: FDA Moves to Block Biopharma Employees From Serving on Advisory Committees, FDA Cuts Outlined in Draft HHS Budget

FDA moves to block biopharma employees from serving on advisory committees

The FDA has issued a new directive barring employees of FDA-regulated biopharma companies from serving on its advisory committees to reduce perceived industry influence and promote greater transparency, while still allowing them to present views and contribute in limited circumstances.

FDA cuts outlined in draft HHS budget

The Trump administration's draft HHS budget proposes an 18.6% cut to FDA congressional funding and broader reductions across the agency, raising concerns about the FDA's operations and potential impacts on drug and device development, though analysts note Congress may ultimately restore much of the proposed funding.

Battling Outdated Regulations in the Trial Master File Space

In this video interview published by Applied Clinical Trials, Rob Jones product manager, TMF practice area, Pharmalex, discusses challenges the trial master file space is currently facing and how it can utilize collaboration in making advancements.

Analysis Reveals Polypharmacy Challenges in Patients With Cancer

A study published in Supportive Care in Cancer found that cancer patients in palliative care take an average of two unnecessary medications, contributing to pill burden and reduced quality of life. The study authors highlighted the effectiveness of pharmacist-physician collaboration, especially through direct communication, in safely deprescribing to improve patient outcomes.

Expert Discusses Transparency and Education for the Current Measles Outbreak

Crystal Hodge, PharmD, emphasizes the importance of transparency, data-driven communication and pharmacist-led education to combat measles outbreaks, address vaccine hesitancy, and rebuild public trust through informed consent, community engagement, and collaboration with health departments.